Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ayahuasca/Healthy Volunteers

Ayahuasca for Healthy Volunteers

42 papers and 6 clinical trials exploring ayahuasca as a treatment for healthy volunteers.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

42 papers
Open Accessindividual

EXPRESS: Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: A randomised [F]FDG-PET Study

This re-analysis of a randomised crossover study (n=14) in healthy men found that buccal DMT plus harmine (pharmahuasca) increased brain glucose metabolism compared with placebo, with widespread rises across the cortex, especially in higher-order networks. The increase was linked to harmine levels, but not to DMT levels or to how intense the experience felt.

Published
June 1, 2026
Journal
Journal of Cerebral Blood Flow and Metabolism
Authors
Egger, K., Bozsak, R., Aicher, H. D. D., Sari, H., Poetzsch, S. N., Rominger, A., Martin-Soelch, C., Smallridge, J. W., Dornbierer, D., Quednow, B. B., Scheidegger, M., Cumming, P.
Open Accessindividual

An exploratory persistent-homology analysis of resting-state fMRI functional connectivity under Ayahuasca

This exploratory brain imaging study (n=9) examined resting-state fMRI connectivity before and after ayahuasca and found a small drop in one measure of topological complexity in the main analysis, but this did not hold up after correction and was not seen when signed correlations were used. Exploratory measures of signal complexity rose slightly but not significantly.

Published
May 30, 2026
Journal
Chaos, Solitons & Fractals
Authors
dos Santos, T. C., de Araujo, D. B., Felippe, H., Miranda, J. G. V., Palhano-Fontes, F., Silva do Rosário, R., Onias, H., Viol, A., Viswanathan, G. M., Santos, F. A.
Open Accessindividual

Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat

This secondary analysis of a randomised controlled trial of DMT/harmine in experienced meditators found that meditation under DMT-harmine differed from placebo in its thematic and experiential profile while still sharing some semantic features. Using NLP-based analysis of phenomenological interviews, the study also suggested overlap between meditative and psychedelic states and highlighted the strong influence of context and spiritual framing on subjective experience.

Published
March 18, 2026
Journal
Scientific Reports
Authors
Schlomberg, J. T. T., Meling, D., Grylka, R., Vasella, E. A., Augustinovic, D., Scheidegger, M.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations

In a double-blind, placebo-controlled trial of 50 volunteers, ayahuasca produced robust perceptual, emotional and mystical experiences alongside EEG changes (notably reduced global alpha and increased frontomedial delta and right-posterior theta/beta), with acute lower theta linked to stronger mystical effects and baseline theta and beta oscillations predicting interoceptive and emotional responses.

Published
December 4, 2025
Journal
Journal of Psychopharmacology
Authors
Silva-Costa, N., Pessoa, J. A., Andrade, K. C., Mota-Rolim, S., Palhano-Fontes, F., Araujo, D. B., Wießner, I.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
August 15, 2025
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.

Clinical Trials

6 trials
CompletedPhase I

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach (HaD-PET)

Phase I, randomised, single-blind crossover FDG-PET study (n≈17) assessing acute cerebrometabolic effects of an oral harmine+DMT formulation versus placebo in healthy male volunteers.

Started
January 22, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06252506
Unknown statusPhase I

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

Open-label, Phase I dose-ranging safety study (n=12) in healthy adults testing single oral doses of SM-001 (0.5, 1.0, 2.0 mL/kg) to assess safety and plasma biomarkers.

Started
October 1, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05894902
Not yet recruitingPhase NA

A pilot study testing the feasibility of a single microdose of ayahuasca alkaloids on neurotransmitters, inflammation marker levels, safety, and mood in healthy adult volunteers

This interventional pilot study (n=4; target n=5) tests a single oral microdose (30 mg ayahuasca alkaloids co-formulated with l‑epicatechin complex) in healthy adults aged 25–60 to assess blood neurotransmitters, IL-6, safety, and mood.

Started
May 14, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12623000155695p
CompletedPhase I

Mindfulness and Psychedelics

This double-blind, placebo-controlled trial (n=40) aims to investigate the potential neurophysiological synergy effects between mindfulness meditation and psychedelics, particularly ayahuasca, on experienced meditators.

Started
February 20, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05780216
Not yet recruitingPhase I

An open label study to evaluate the safety, tolerability, and subjective effects of two dimethyltryptamine (DMT) and harmala alkaloid containing formulations in healthy volunteers

Randomised crossover Phase I healthy volunteer study (n=8) assessing two oral DMT–harmala formulations with dose escalation (1.0→1.4 mg/kg DMT; 4→5.6 mg/kg harmala).

Started
November 5, 2022
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ACTRN12622001315707
CompletedPhase I

Study of Harmine in Healthy Subjects

Phase I open-label, single-ascending-dose study (n=27) using CRM to determine the maximum tolerated oral dose of harmine in healthy volunteers.

Started
September 13, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05526430

Explore further

Search all Ayahuasca papers Search all Healthy Volunteers trials Full Ayahuasca profile Full Healthy Volunteers profile